GEM 21S Equimatrix Heli Products Mucograft References Download Center Video Education Center Lecture Materials
Professionals Patients Contact Us About Us

About Us

Since 1994, Osteohealth® has been distributing bone grafting products used by dental professionals throughout the world. As the leader in regeneration, Osteohealth Company's overriding goal is to develop and distribute, with professionalism and integrity, products of the highest quality that have been scientifically and clinically proven to enhance patient care.

Osteohealth® has also dedicated its efforts towards the development of new products based upon the principles of tissue engineering. In this regard, Osteohealth® has made a major commitment to develop and distribute to health care providers, in the field of dentistry, superior products engineered to regenerate bone and other tissues.

Introduced by Osteohealth in 2005, GEM 21S® Growth-factor Enhanced Matrix is an innovative, completely synthetic regenerative technology that combines a recombinant human platelet derived growth factor-BB and Beta-Tricalcium Phosphate.

Osteohealth® Company is one of five divisions of Luitpold Pharmaceuticals, Inc., which is a group company of Daiichi Sankyo Co., Ltd.

Luitpold Pharmaceuticals, Inc.

Luitpold Pharmaceuticals is an innovative manufacturer and distributor of a wide spectrum of drugs and medical devices.

A wholly owned subsidiary of Daiichi Sankyo Co., Ltd. of Japan, Luitpold Pharmaceuticals has earned a reputation for providing the highest levels of customer service to healthcare professionals, clinics, and hospitals across the United States. Luitpold’s team of highly skilled professionals is committed to providing superior quality in everything they do. Luitpold Pharmaceuticals’ four subsidiaries and business divisions are a reflection of that commitment:
  • Osteohealth® Company, our cutting-edge biomaterials division, markets natural source and synthetics products used in dental bone grafting and guided bone regeneration
  • American Regent, Inc., markets and distributes quality injectable products across a broad range of therapeutic areas, which are widely used in healthcare facilities throughout the United States
  • Luitpold Animal Health division manufactures pharmaceutical products for the treatment of equine and canine joint disease  
  • Contract Manufacturing Division is a developer and supplier of custom-manufactured injectable products for the pharmaceutical and biotechnology industries

Luitpold’s corporate headquarters are located at One Luitpold Drive, Shirley, NY and house our commercial, financial, and administrative operations. In addition, Shirley, NY is the home of our state-of-the-art manufacturing facility and our cutting-edge research labs.

Industry Affiliations

Osteohealth is an active participant and supporter of a number of industry associations including:

Academy of Osseointegration
American Academy of Implant Dentistry
American Academy of Periodontology
American Association of Oral & Maxillofacial Surgeons

International Congress of Oral Implantologists 

Osteohealth Company   |   Contact Us   |   © 2014 Luitpold Pharmaceuticals, Inc. Company   |   Privacy Policy   |   Terms of Use

June 29, 2016 – Effective today, Ken Keller has been newly appointed as President and CEO of Luitpold Pharmaceuticals, in addition to his current position as President, Daiichi Sankyo Administrative and Commercial, Daiichi Sankyo, Inc.

With more than 25 years of experience in the pharmaceutical industry in commercial leadership and joint venture leadership, Mr. Keller will now oversee both the Daiichi Sankyo, Inc. Commercial organization and Luitpold Pharmaceuticals, Inc.

Mr. Keller joined Daiichi Sankyo, Inc. in 2014 and has also served on the Luitpold Board of Directors since 2015. He has successfully led the Daiichi Sankyo, Inc. US commercial organization as it begins its transformation to a specialty focused company.

“While Luitpold and Daiichi Sankyo US businesses serve different customers and markets, they each bring to the table important strengths and focus that are essential to the continued success and growth of the Daiichi Sankyo Group,” said Ken Keller. “I look forward to working with the Luitpold team and driving even further success in the future.”

Luitpold Pharmaceuticals, Inc. is a Daiichi Sankyo Group Company headquartered in Shirley, NY, and manufactures more than 80 pharmaceutical products.